Search results
18 sie 2021 · Initially backed by Novartis and Bayer's venture arms, immuno-oncology biotech Immunitas has secured another $58 million to push a new class of checkpoint inhibitors on to the next stop.
Tematy dnia
21 cze 2021 · LONDON, June 21, 2021 /PRNewswire/ -- Board level executives from Novartis, Bayer and Boehringer Ingelheim, amongst many more, will showcase their long-term visions for healthcare as a...
5 dni temu · Bayer CEO says recovery on track as key drug products shine. Bayer has joined its peers among European drugmakers with a hike in pharma forecasts for the year, as it recorded a rise in group...
Stories. Media Release Sep 18, 2024. New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients. Key Release Sep 17, 2024. FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer. Media Release Sep 16, 2024.
20 lip 2021 · Board level executives from Novartis, Bayer and Boehringer Ingelheim, amongst many more, will showcase their long-term visions for healthcare as a response to the COVID-19 pandemic, by joining the speaker faculty at Reuters Events Pharma Europe 2021.
21 cze 2021 · LONDON, June 21, 2021 /PRNewswire/ -- Board level executives from Novartis, Bayer and Boehringer Ingelheim, amongst many more, will showcase their...
6 dni temu · Novartis has inked a deal potentially worth more than $1 billion with Flagship-founded Generate:Biomedicines to develop protein therapeutics across multiple indications. The companies did not ...
